Why the study?
Does periprocedural dabigatran reduce bleeding and thromboembolic complications compared to uninterrupted warfarin in patients undergoing catheter ablation of atrial fibrillation?
Does periprocedural dabigatran reduce bleeding and thromboembolic complications compared to uninterrupted warfarin in patients undergoing catheter ablation of atrial fibrillation?
Periprocedural dabigatran (110 mg twice daily) is a safe alternative to uninterrupted warfarin during atrial fibrillation ablation, significantly reducing total bleeding complications without increasing thromboembolic risk.
No takes yet. Share an insight, caveat, or question.
Dabigatran was associated with fewer bleeding complications than warfarin in AF ablation; leaves open whether it should replace uninterrupted anticoagulation.
Kaseno et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: